Efficacy of HPV vaccine in preventing cervical cancer in the Tomsk region

Author:

Ananina O.  A.1ORCID,Kolomiets L.  A.2ORCID,Zhuykova L. D.1ORCID,Churuksaeva O. N.1ORCID,Chernyshova A.  L.1ORCID,Villert A.  B.1ORCID,Pikalova L. V.1ORCID,Mosolkov V.  Yu.3

Affiliation:

1. Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences

2. Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Siberian State Medical University, Ministry of Health of Russia

3. Seversk Clinical Hospital, Siberian Federal Scientific Clinical Center of Federal Medicobiological Agency of Russia

Abstract

   Background. The age-standardized cervical cancer incidence rate in the Tomsk region in 2021 was consistently higher than the average for the Russian Federation (21.2 / 100,000 versus 13.6 / 100,000 women). Primary prevention of cervical cancer is best achieved by human papillomavirus (HPV) vaccination of girls.   Aim. To evaluate HPV vaccine efficacy for the prevention of cervical cancer in the Tomsk region within the framework of implementation of two regional programs: “Prevention of gynecological cancer and rehabilitation of women diagnosed with gynecological cancer in 2008–2010” and “Urgent measures to improve cancer care for the population of the Tomsk region in 2011–2013”.   Material and methods. We studied the tolerability and efficacy of HPV vaccination for the prevention of HPV-associated cervical cancer in 439 vaccinated girls aged 9–26 years during a follow-up time of 14-years.   Results. The assessment of a 14-year follow-up study of the impact of HPV vaccination on HPV-associated cervical lesions has shown that HPV vaccine is safe and 100 % effective.   Conclusion. Further prospects for primary prevention of cervical cancer before the introduction of vaccines against HPV infection in the national immunization schedule indicates the feasibility and real clinical effectiveness of the introduction of regional and regional programs with the development of a mathematical model for optimizing financial costs for primary prevention of cervical cancer, taking into account demographic parameters and socio-economic damage from cervical cancer in the study area.

Publisher

Publishing House ABV Press

Subject

Pharmacology (medical),Obstetrics and Gynecology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference26 articles.

1. Kolomiets L. A., Churuksaeva O. N., Chernyshova A. L. et al. Vaccination against HPV – primary prevention of cervical cancer. 2nd edn., rev. and add. Tomsk: Publishing House “Pechatnaya manufaktura”, 2011. 116 p. (In Russ.)

2. Churuksaeva O. N., Kolomiets L. A. Oncotropic human papillomavirus infection and prognosis of cervical cancer. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology 2013; (1): 82–7. (In Russ.)

3. International Human Papillomavirus Reference Center. Human papillomavirus reference clones, 2014. Available at: https://www.hpvcenter.se/human_reference_clones/

4. Khryanin A. A., Reshetnikov O. V., Kolomiyets L. A. New horizons for the prevention of the papilloma viral infection. Vestnik dermatologii i venerologii = Bulletin of Dermatology and Venereology 2009; (5): 49–55. (In Russ.)

5. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec 2014; 89 (43): 465–91.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3